Evaluating the risk factors for developing resistance to parenteral therapy for tubo‐ovarian abscess: A case–control study
article
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
This case-control study identified tubo-ovarian abscess diameter greater than 5 cm as a significant risk factor for parenteral antibiotic therapy failure.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
AIM: The aim of this study was to identify factors that can predict the resistance to parenteral therapy in patients with tubo-ovarian abscesses (TOA). MATERIAL AND METHODS: We conducted a case-control study involving 55 admitted patients with TOA. The subjects eligible for this study included 28 patients who failed antibiotic therapy and required surgery (surgical cases) and 27 patients who were conservatively cured (control cases). The clinical characteristics of the patients on admission were reviewed. Logistic regression analysis was performed after univariate analysis to identify potentially important variables and to calculate odds ratios with 95% confidence intervals. RESULTS: As per the univariate analysis, compared to the control cases, the surgical cases were older (40.4 vs 31.5 years), had higher white blood cell counts (14000 vs 11828 cells/mm³), higher C-reactive protein levels (16.1 vs 7.6 mg/dL), and a larger abscess diameter (6.6 vs 3.9 cm). There were no significant differences in gravidity, parity, body temperature, rate of endometrial cyst formation, and Chlamydia trachomatis infection rates between the groups. Multiple logistic regression analysis indicated that the only statistically significant risk factor predicting parenteral antibiotic therapy failure was the abscess diameter >5 cm (odds ratio = 69.6; 95% confidence interval = 9.3-527, P 5 cm is an important factor for predicting the failure of antibiotic therapy in patients with TOA. Moreover, it is useful for determining whether patients with TOA should be surgically treated.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (2)
References (22)
- doi:10.1097/ogx.0b013e3181b8b0d6 via openalex
- doi:10.1111/j.1447-0756.1997.tb00867.x via openalex
- doi:10.1002/(sici)1098-0997(2000)8:2<88::aid-idog5>3.0.co;2-x via openalex
- doi:10.1093/clinids/5.5.876 via openalex
- doi:10.1097/00003081-199306000-00022 via openalex
- doi:10.1016/0002-9378(56)90174-0 via openalex
- doi:10.1097/00003081-196903000-00015 via openalex
- doi:10.1111/j.0001-6349.2005.00509.x via openalex
- doi:10.1016/0002-9378(64)90604-0 via openalex
- doi:10.1016/s0001-2998(88)80041-2 via openalex
- W2418069093 via openalex
- W4300928773 via openalex
- W6717231745 via openalex
- doi:10.1016/j.ajog.2005.06.019 via openalex
- doi:10.1016/j.fertnstert.2004.01.032 via openalex
- doi:10.1016/0002-9378(85)90392-8 via openalex
- doi:10.2214/ajr.158.3.1738998 via openalex
- doi:10.1046/j.1469-0705.1998.12010056.x via openalex
- doi:10.1016/s0015-0282(16)58088-1 via openalex
- doi:10.1016/0002-9378(80)91107-2 via openalex
- doi:10.1016/s0002-9378(98)70333-3 via openalex
- doi:10.1016/j.ejogrb.2003.10.032 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-10T11:01:14.481557+00:00
- unpaywall
- last seen: 2026-08-12T06:43:03.944938+00:00
License: CC0
· commercial use OK